The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Deferum     3-hydroxy-1,2-dimethyl- pyridin-4-one

Synonyms: Ferriprox, Kelfer, deferiprone, HK-1, APO-66, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of deferiprone


High impact information on deferiprone


Chemical compound and disease context of deferiprone


Biological context of deferiprone


Anatomical context of deferiprone

  • Specific labelling of a chelatable "cold" iron pool in hepatocytes by 59Fe derived from ferritin showed this pool to be equally accessible to parenteral doses of both chelators and also to oral 1,2-dimethyl-3-hydroxypyrid-4-one, which is an effective oral iron chelating agent that removes iron from parenchymal cells [12].

Associations of deferiprone with other chemical compounds


Gene context of deferiprone


Analytical, diagnostic and therapeutic context of deferiprone


  1. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. Kontoghiorghes, G.J., Aldouri, M.A., Sheppard, L., Hoffbrand, A.V. Lancet (1987) [Pubmed]
  2. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. al-Refaie, F.N., Wonke, B., Hoffbrand, A.V., Wickens, D.G., Nortey, P., Kontoghiorghes, G.J. Blood (1992) [Pubmed]
  3. The oral iron chelator, 1,2-dimethyl-3-hydroxypyrid-4-one reduces hepatic-free iron, lipid peroxidation and fat accumulation in chronically ethanol-fed rats. Sadrzadeh, S.M., Nanji, A.A., Price, P.L. J. Pharmacol. Exp. Ther. (1994) [Pubmed]
  4. Synthesis and iron(III) binding properties of 3-hydroxypyrid-4-ones derived from kojic acid. Molenda, J.J., Basinger, M.A., Hanusa, T.P., Jones, M.M. J. Inorg. Biochem. (1994) [Pubmed]
  5. A comparison of the iron-clearing properties of 1,2-dimethyl-3-hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamine. Bergeron, R.J., Streiff, R.R., Wiegand, J., Luchetta, G., Creary, E.A., Peter, H.H. Blood (1992) [Pubmed]
  6. Chelating agents used for plutonium and uranium removal in radiation emergency medicine. Fukuda, S. Current medicinal chemistry. (2005) [Pubmed]
  7. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects. Kontoghiorghes, G.J., Pattichis, K., Neocleous, K., Kolnagou, A. Current medicinal chemistry. (2004) [Pubmed]
  8. Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia. Matsui, D., Klein, J., Hermann, C., Grunau, V., McClelland, R., Chung, D., St-Louis, P., Olivieri, N., Koren, G. Clin. Pharmacol. Ther. (1991) [Pubmed]
  9. Iron-dependent activation of NF-kappaB in Kupffer cells: a priming mechanism for alcoholic liver disease. Xiong, S., She, H., Sung, C.K., Tsukamoto, H. Alcohol (2003) [Pubmed]
  10. Studies of in vivo iron mobilization by chelators in the ferrocene-loaded rat. Florence, A., Ward, R.J., Peters, T.J., Crichton, R.R. Biochem. Pharmacol. (1992) [Pubmed]
  11. Efficacy of deferiprone in the treatment of acute iron intoxication in rats. Fassos, F.F., Berkovitch, M., Daneman, N., Koren, L., Cameron, R.G., Klein, J., Falcitelli, C., St Louis, P., Daneman, R., Koren, G. J. Toxicol. Clin. Toxicol. (1996) [Pubmed]
  12. Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats. Kontoghiorghes, G.J., Sheppard, L., Hoffbrand, A.V., Charalambous, J., Tikerpae, J., Pippard, M.J. J. Clin. Pathol. (1987) [Pubmed]
  13. Reversed-phase high-performance liquid chromatography of non-transferrin-bound iron and some hydroxypyridone and hydroxypyrone chelators. el-Jammal, A., Templeton, D.M. J. Chromatogr. B, Biomed. Appl. (1994) [Pubmed]
  14. Studies of aluminium mobilization in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Kontoghiorghes, G.J., Barr, J., Baillod, R.A. Arzneimittel-Forschung. (1994) [Pubmed]
  15. Impaired erythropoietin responsiveness to the anaemia in rheumatoid arthritis. A possible inverse relationship with iron stores and effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Vreugdenhil, G., Kontoghiorghes, G.J., Van Eijk, H.G., Swaak, A.J. Clinical and experimental rheumatology. (1991) [Pubmed]
  16. Role of iron in NF-kappa B activation and cytokine gene expression by rat hepatic macrophages. Lin, M., Rippe, R.A., Niemelä, O., Brittenham, G., Tsukamoto, H. Am. J. Physiol. (1997) [Pubmed]
  17. Molecular factors affecting the complex formation between deferiprone (L1) and Cu(II). Possible implications on efficacy and toxicity. Pashalidis, I., Kontoghiorghes, G.J. Arzneimittel-Forschung. (2001) [Pubmed]
  18. Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous beta-thalassemia. Fassos, F.F., Klein, J., Fernandes, D., Matsui, D., Olivieri, N.F., Koren, G. Clin. Pharmacol. Ther. (1994) [Pubmed]
  19. Differential toxicity of alpha-keto hydroxypyridine iron chelators and desferrioxamine to human haemopoietic precursors in vitro. Cunningham, J.M., al-Refaie, F.N., Hunter, A.E., Sheppard, L.N., Hoffbrand, A.V. Eur. J. Haematol. (1994) [Pubmed]
  20. Effects of iron loading on uptake, speciation, and chelation of iron in cultured myocardial cells. Parkes, J.G., Hussain, R.A., Olivieri, N.F., Templeton, D.M. J. Lab. Clin. Med. (1993) [Pubmed]
  21. Chelators affecting iron absorption in mice. Kontoghiorghes, G.J. Arzneimittel-Forschung. (1990) [Pubmed]
WikiGenes - Universities